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The Protection of Personal Information Act (POPIA) No. 4 of 2013[1] 
is the first comprehensive data-protection regulation to be passed in 
South Africa (SA). Its purpose is to give effect to the constitutional 
right to privacy by regulating the way in which personal information 
must be processed, to balance the right to privacy against other 
rights, such as the right to access information, and to establish an 
Information Regulator to ensure that the rights protected by POPIA 
are respected. POPIA is similar to the European General Data 
Protection Regulation (GDPR), which came into force on 25 May 2018 
and has changed the regulation of data protection in the European 
Union (EU). 
Both the GDPR and POPIA will possibly have an impact on 
health research, including biobanks, in SA. At the heart of biobanks 
is the large-scale sharing of samples and data. International 
collaborative projects, such as Human Heredity and Health in 
Africa (H3Africa) and Bridging Biobanking and Biomedical 
Research across Europe and Africa (B3Africa), have resulted in a 
growth in biobanks in SA and increased the flow of samples and 
data across borders. The National Health Act No. 61 of 2003[2] and 
the Regulations relating to the import and export of human tissue, 
blood, blood products, cultured cells, stem cells, embryos, zygotes 
and gametes, 2012,[3] primarily focus on the legal requirements for 
obtaining and exporting a biological sample. Specifically, an export 
permit is required prior to the exportation of a sample only and 
not before data export. The Material Transfer Agreement (MTA) of 
Human Biological Materials, 2018,[4] and the National Department 
of Health ethics guidelines, 2015,[5] do have some provisions for the 
transfer of data.
The GDPR and POPIA will change the abovementioned infor-
mation. While a full analysis of the GDPR and its impact on biobanks 
are beyond the remit of this article, one should note that it will have 
impact on the transfer of data from the EU to SA. Data can only be 
transferred to ‘third countries’ (i.e. countries outside of the EU) if 
the data have the same level of protection as in the EU. Transfers 
can only take place if they are subject to an adequacy decision or if 
appropriate safeguards are put in place. An adequacy decision relates 
to the European Commission having decided that a third country 
has appropriate safeguards with regard to data protection. To obtain 
an adequacy decision, a proposal from the European Commission, 
an opinion of the European Data Protection Board and an approval 
from representatives of EU countries must be obtained, as well as the 
adoption of the decision by the European  Commissioner. This will 
possibly occur when third countries enact legislation that guarantees 
the same protection as that contained in the GDPR. It is possible 
that, when in force, POPIA will satisfy this requirement, but this is 
currently unclear. Should a third country be on the Commission’s 
approved list, specific authorisation will not be required to transfer 
data. If a third country is not on the relevant list or is awaiting 
approval, data can still be transferred abroad provided there are 
appropriate safeguards in place, which could include a legally binding 
agreement. It remains to be seen whether MTAs will be deemed 
to provide sufficient safeguards. Therefore, since 25 May 2018, a 
biobank in SA that is collaborating with EU organisations, must 
ensure that it is compliant with the GDPR, or be subject to fines 
or contractual liability of up to EUR20 million or 4% of the annual 
worldwide turnover (whichever is greater).
The GDPR has strict provisions for the processing of sensitive 
data, which include genetic data. In response to criticisms from 
researchers, a ‘research exemption’ was inserted into the GDPR 
and sensitive data can be processed without adhering to the very 
strict consent requirements as outlined in Article 9(2)(a). POPIA 
similarly contains restrictions on the use of sensitive data, but 
has no research exemption. It provides that an industry can apply 
to have a code of conduct accredited, which is being developed 
for SA universities. This code should offer detailed guidance to 
research biobanks on the implementation of POPIA. In the interim, 
a biobank must consider how to govern its data to ensure that it is 
POPIA compliant. This article considers the provisions of POPIA 
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that will potentially have the greatest impact on biobanks in SA. 
In particular, it focuses on the principle of data minimisation, 
requirements pertaining to the transfer of data abroad, consent 
provisions and a discussion on the ‘responsible person’. Although 
POPIA does not contain research exemption, careful navigating of 
the Act shows that there are certain exceptions to the strict consent 
provisions in the research context.
Consent under the Protection of 
Personal Information Act
According to SA’s research ethics framework, samples can be 
collected using the broad consent model for secondary use (as 
defined in the 2015 guidelines as ‘use in research of materials 
or data originally collected for other purposes’[5]), subject to 
REC oversight. Samples can be shared with research institutions, 
both locally and internationally, subject to certain approvals. 
The National Department of Health guidelines place similar 
requirements on data and on samples. The question now facing 
biobanks is whether POPIA places additional requirements on the 
use, re-use and sharing of data. 
POPIA requires that the processing of personal data must be 
lawful and must be done in a reasonable manner that does not 
infringe the privacy of the data subject (section 11). Section 13(1) 
states that personal information (as defined in Article 1, including 
health-related data) ‘must be collected for a speciﬁc, explicitly 
deﬁned and lawful purpose related to a function or activity of the 
responsible party’. With regard to the use of personal information 
for research, consent will be required. Section 1 states that consent 
must be ‘voluntary, specific and informed’, i.e. it must be specific 
and only for a clearly defined purpose when data are obtained. It 
would appear that POPIA rules out broad consent, as the research 
for subsequent processing of data may not be known at the time of 
data collection. However, there are certain exceptions to these strict 
consent provisions that are applicable to biobanks. 
Section 15(1) states that the responsible party can further process 
personal information while not infringing on section 13, as further 
processing is compatible with the original purpose for which the data 
are collected, taking the following into account:
(a)  the relationship between the purpose of the intended further 
processing and the purpose for which the information has 
been collected
(b) the nature of the information 
(c)  the consequences of the intended further processing for the 
data subject
(d) the manner in which the information has been collected
(e) any contractual rights and obligations between the parties.
Further processing refers to processing in addition to that for which 
the personal data were originally collected and would cover instances 
where personal data are initially collected for one research project, 
but subsequently used for other research projects. This subsection 
would seem to suggest that if the research is closely linked to that for 
which the data were collected, the responsible party can re-use the 
data without obtaining consent again. However, section 15(3) will 
perhaps bring most relief to researchers, as it provides four instances 
where further processing of data is permitted: 
• if the data subject consents to this (section 15(3)(a)) 
• if it is necessary to mitigate a serious threat to public health or the life 
or health of a data subject or another individual (section 15(3)(d))
• if further processing is solely for research purposes and the findings 
will not be published in an identifiable form (section 15(3)(e))
• if the responsible party obtains a section 37 exemption (section 15(3)(f)). 
This suggests that broad consent may be permissible in terms of POPIA 
if the subsequent projects are ‘compatible’ (or quite similar) with the 
project for which it was initially collected. The question that now 
faces biobanks is whether they can use data for research that are not 
‘compatible’ with the research for which the data were initially collected. 
There is a general prohibition of the processing of special personal 
information (section 26). This includes ‘religious or philosophical 
beliefs, race or ethnic origin, trade union membership, political 
persuasion, health or sex life or biometric information of a data 
subject’ and genetic data would fall under this prohibition. Under 
section 27(1)(d), special data can be further processed if it is for 
research purposes in the public interest or where it would be 
impossible, or require a disproportionate effort, to ask for consent, 
and there are guarantees put in place that the privacy of the data 
subject will not be disproportionately affected. If these criteria are 
satisfied, it would thus appear that approval from a research ethics 
committee (REC) would be required for the use of data beyond the 
remit of the research provided for in the consent form. 
With regard to the sharing of data, section 12 states that the data 
must be collected directly from the data subject, which implies that 
data cannot be shared with other researchers. Section 12(2) provides 
certain exceptions to that rule and data can be shared with others, 
including whether the data subject consents or where compliance 
is not reasonably practicable. A purposive interpretation of POPIA 
would thus suggest that broad consent is permissible. To be compliant 
with POPIA, if biobanks intend to share data with others for research 
purposes, it must be provided for in the consent form.
Generally, the responsible party decides on the use or re-use of 
data, but there are two instances in which the regulator must be 
involved. First, if any researcher intends to process unique identifiers 
(an identifier that is assigned to a data subject for purposes of 
identification) of a data subject for a purpose other than that for 
which they were collected, or for the purpose of linking them with 
other data, prior authorisation of the regulator must be obtained 
(section 57). Second, if a section 37 exemption is sought, i.e. if a 
responsible party wishes to process personal data that are not within 
the confines of the Act and do not fall under any of the exemptions 
discussed above, an application must be made to the regulator. It must 
be demonstrated that the public interest outweighs any interference 
of the privacy of the data subject, and for biobanks, public interest 
specifically includes research (section 37(2)(e)).
Protection of Personal Information 
Act and data minimisation
Section 10 states that ‘personal information may only be processed 
if, given the purpose for which it is processed, it is adequate, 
relevant and not excessive’ with Section 11 providing the grounds 
for the lawful processing of data. This is part of a movement towards 
minimising the volume of data collected. It will undoubtedly be 
problematic in the biobank setting, where the purpose is to collect 
large quantities of samples and data for unanticipated future use. 
However, the exact impact of this section in the research context 
remains to be seen. It will in part depend on how the phrase ‘purpose 
for which it is processed’ is interpreted. When this requirement is 
read with section 15 in relation to further processing (or secondary 
use), it would appear that obtaining data for research purposes would 
satisfy this requirement without it being necessary to specify the 
exact type of research that the data will be used for. In the interim, 
biobanks should review the data that they collect and ensure that they 
do not obtain excessive data, bearing in mind the requirements for 
the informed consent document set out in the Department of Health 
guidelines, 2015.[5]
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Protection of Personal Information 
Act and the transfer of data abroad
Section 72 governs the transfer of data to a third country. If the 
receiving country is not subject to a law that provides an adequate 
level of data protection as measured against the levels of protection 
envisaged by POPIA, the personal data cannot be transferred unless the 
institution in the receiving country has agreed to adhere to POPIA, or 
if the research subject consents to the transfer to this country (section 
72(1)(a) and (b)). The same rules apply if the recipient institution wants 
to transfer personal data to another country. In the research context, 
this provision will have to be complied with through the conclusion 
of an MTA or data transfer agreements (DTAs). The requirements 
set forth in the recently gazetted MTA of Human Biological Materials 
must now also be followed and RECs must review and approve 
proposals to transfer data and the MTA. 
The transfer can also take place if it is in the interest of the research 
subject, it is impractical to obtain consent, and if it is likely that the 
research subject would have consented if asked (section 72(1)(e)). 
This exception only applies if the research is in the interest of the data 
subject. In general, it can be argued that all health research should 
be in the general interest of the public. Whether this argument will 
persuade the Information Regulator remains to be seen, as it will 
be weighed against the potential infringement of the data subjects’ 
privacy as a result of the transfer of the personal data to a country 
where there is no data protection regimen in place. 
Protection of Personal Information 
Act and the responsible party
Throughout the Act, reference is made to the ‘responsible party’. It is 
defined as ‘a public or private body or any other person which, alone 
or in conjunction with others, determines the purpose of and means 
for processing personal information’. It is the same definition as that 
of the ‘data controller’ (GDPR). In the biobank context, this could 
be interpreted as being the institution where the biobank is situated, 
principal investigator, REC or data access committee. Section 8 states 
that the responsible party has to ensure compliance with the Act. 
From this, it would appear that the institution will assume overall 
responsibility for ensuring that its biobanks comply with the Act, 
and the institution will be subject to any fines arising from a breach 
of the Act. 
In practice, it is likely that this responsibility will be delegated to 
another body. As RECs are currently the oversight bodies for the use 
and re-use of biological samples, authority will possibly also be vested 
in them to ensure compliance with POPIA. While this is certainly 
the most practical solution, the capacity and resources of RECs are 
a concern. The capacity of RECs to review complex projects, such 
as genomic and biobanking research, has been a subject of debate[6] 
and it is unclear whether SA RECs would have the capacity to review 
protocols that pertain to data. Biobanks will need to be provided with 
considerable support in the drafting of their data management plans 
to ensure compliance with the GDPR and POPIA. Considering the 
large fines that the data controller can be subject to in the event of 
non-compliance with the GDPR or the loss of European partnerships or 
funding, it is in the interest of universities that their biobanks are compliant 
with the relevant laws. 
One possible solution is the establishment of a data access committee. 
This committee should comprise individuals who have the necessary 
legal, ethical and scientific expertise required to review and monitor 
research that proposes to use data. It will thus avoid increasing the 
workload of the already over-burdened RECs. These committees 
should sit within the REC framework, as any research project will 
require a full ethical review. However, universities must set aside an 
additional budget for these committees to ensure that they are fully 
resourced, without taking away from the current REC budget. 
Conclusion 
POPIA will bring changes to the management and use of biological 
data. With no research exemption to the strict consent requirement 
similar to that in the GDPR, it requires careful navigation to fully 
assess its impact on research and secondary use of research in general 
and biobanks in particular in SA. It is therefore recommended 
that SA biobanks review their consent forms. These forms should 
explicitly state that data may be shared with other researchers, 
including collaborators who are abroad. Although it appears that 
data can be re-used for research purposes other than the purposes 
for which they were originally obtained, owing to the principle of 
data minimisation and the emphasis on ensuring that the secondary 
use of data is compatible with the original purpose, biobanks should 
re-use data for ‘compatible’ research as far as possible. Finally, in the 
sharing of data, biobanks must ensure that their MTAs are robust and 
be certain that the receiving institution is legally obliged to adhere to 
the strict provisions of POPIA.
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